Medically reviewed by Steffini Stalos, DO Hemophilia disease is a rare inherited bleeding disorder. People with this genetic ...

Children with hemophilia have problems with dynamic balance and face an increased risk of falls compared with healthy peers, ...

HC Bioscience is shutting down after conducting preclinical models for a transfer RNA (tRNA) asset designed to treat ...

Hemophilia A is a disorder that makes a person predisposed to bleeding. This can cause issues ranging from prolonged bleeding from a minor wound to bleeding emergencies. The condition is caused by ...

People with hemophilia A bleed and bruise easily, and their blood takes a long time to form clots. Hemophilia A is a rare, serious condition that has no cure, but is treatable. Hemophilia A is ...

Treatment involved an antithrombin-based dose regimen targeting antithrombin levels between 15% and 35%, starting at 50 mg once every 2 months, individually adjusted to 20, 50, or 80 mg monthly or 20 ...

“Gene therapy for hemophilia A with the use of lentiviral vector-transduced autologous HSCs resulted in stable factor VIII ...

Columnist Alliah Czarielle urges those with hemophilia to remember the power of movement, even if they sense that activity invites trouble.

Rising Prevalence of Hemophilia, Increasing Adoption of Recombinant Therapies, and Breakthroughs in Gene Therapy Propel Market Growth.Pune, March 12, 2025 (GLOBE NEWSWIRE) -- Hemophilia Market Size & ...

The changes at Spark follow Roche's decision last year to halt development of a gene therapy for hemophilia A that was the main asset at Spark when Roche acquired it and related layoffs.

EMERYVILLE, Calif., March 17, 2025 (GLOBE NEWSWIRE) -- Metagenomi, Inc. (Nasdaq: MGX), a precision genetic medicines company ...

One Indianapolis family is packing their bags for Washington, D.C. to advocate for better healthcare policies for those with ...